僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma （RRMM）. Elotuzumab results in improved response and outcome when combined with other antimyeloma agents